ResMed Cash Conversion Cycle from 2010 to 2024

RMD Stock  USD 249.02  0.31  0.12%   
ResMed's Cash Conversion Cycle is increasing over the years with slightly volatile fluctuation. Cash Conversion Cycle is expected to dwindle to 133.06. During the period from 2010 to 2024 ResMed Cash Conversion Cycle annual values regression line had geometric mean of  150.63 and mean square error of  685.13. View All Fundamentals
 
Cash Conversion Cycle  
First Reported
2010-12-31
Previous Quarter
170.32556192
Current Value
133.06
Quarterly Volatility
30.13122361
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ResMed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ResMed's main balance sheet or income statement drivers, such as Depreciation And Amortization of 227 M, Interest Expense of 48 M or Total Revenue of 4.9 B, as well as many indicators such as Price To Sales Ratio of 4.26, Dividend Yield of 0.0138 or PTB Ratio of 4.77. ResMed financial statements analysis is a perfect complement when working with ResMed Valuation or Volatility modules.
  
Check out the analysis of ResMed Correlation against competitors.

Latest ResMed's Cash Conversion Cycle Growth Pattern

Below is the plot of the Cash Conversion Cycle of ResMed Inc over the last few years. It is ResMed's Cash Conversion Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ResMed's overall financial position and show how it may be relating to other accounts over time.
Cash Conversion Cycle10 Years Trend
Slightly volatile
   Cash Conversion Cycle   
       Timeline  

ResMed Cash Conversion Cycle Regression Statistics

Arithmetic Mean153.31
Geometric Mean150.63
Coefficient Of Variation19.65
Mean Deviation20.66
Median153.65
Standard Deviation30.13
Sample Variance907.89
Range130
R-Value0.55
Mean Square Error685.13
R-Squared0.30
Significance0.03
Slope3.69
Total Sum of Squares12,710

ResMed Cash Conversion Cycle History

2024 133.06
2023 170.33
2022 226.54
2021 196.09
2020 155.9
2019 142.56
2018 153.8

About ResMed Financial Statements

ResMed stakeholders use historical fundamental indicators, such as ResMed's Cash Conversion Cycle, to determine how well the company is positioned to perform in the future. Although ResMed investors may analyze each financial statement separately, they are all interrelated. For example, changes in ResMed's assets and liabilities are reflected in the revenues and expenses on ResMed's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ResMed Inc. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Conversion Cycle 170.33  133.06 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:
Check out the analysis of ResMed Correlation against competitors.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ResMed. If investors know ResMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ResMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.416
Dividend Share
1.97
Earnings Share
7.53
Revenue Per Share
32.711
Quarterly Revenue Growth
0.111
The market value of ResMed Inc is measured differently than its book value, which is the value of ResMed that is recorded on the company's balance sheet. Investors also form their own opinion of ResMed's value that differs from its market value or its book value, called intrinsic value, which is ResMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ResMed's market value can be influenced by many factors that don't directly affect ResMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ResMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if ResMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ResMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.